Investors

Events and Presentations

Analyst Coverage

Corporate Governance

Investor Contacts & Alerts

News Releases

Month Year

Month Year

Oct 15, 2020

Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital
Oct 7, 2020

Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings
Sep 16, 2020

Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference
- Photos 1
Sep 14, 2020

Evofem Biosciences to Present Data at the 2020 STD Prevention Virtual Conference from Phase 2b Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

- Company plans to initiate Phase 3 STI trial by the end of 2020 -
Sep 8, 2020

Evofem Biosciences Announces U.S. Commercial Launch of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal, On-Demand Prescription Contraceptive Vaginal Gel

- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -

Show per page